

# Alcaligenes faecalis metallo- $\beta$ -lactamase in extensively drug-resistant *Pseudomonas aeruginosa* isolates

Li, Yue; Zhu, Yiwei; Zhou, Wanqing; Chen, Zhongju; Moran, Robert A; Ke, Huanhuan; Feng, Yu; van Schaik, Willem; Shen, Han; Ji, Jingshu; Ruan, Zhi; Hua, Xiaoting; Yu, Yunsong

DOI:

[10.1016/j.cmi.2021.11.012](https://doi.org/10.1016/j.cmi.2021.11.012)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Li, Y, Zhu, Y, Zhou, W, Chen, Z, Moran, RA, Ke, H, Feng, Y, van Schaik, W, Shen, H, Ji, J, Ruan, Z, Hua, X & Yu, Y 2021, 'Alcaligenes faecalis metallo- $\beta$ -lactamase in extensively drug-resistant *Pseudomonas aeruginosa* isolates', *Clinical Microbiology and Infection*. <https://doi.org/10.1016/j.cmi.2021.11.012>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1 *Alcaligenes faecalis* metallo- $\beta$ -lactamase in extensively drug-resistant *Pseudomonas*  
2 *aeruginosa* isolates

3 **Running Title:** *Alcaligenes faecalis* metallo- $\beta$ -lactamases

4 Yue Li<sup>1,2,3#</sup>, Yiwei Zhu<sup>1,2,3#</sup>, Wanqing Zhou<sup>4#</sup>, Zhongju Chen<sup>5#</sup>, Robert A. Moran<sup>6</sup>,  
5 Huanhuan Ke<sup>7</sup>, Yu Feng<sup>7</sup>, Willem van Schaik<sup>6</sup>, Han Shen<sup>4</sup>, Jingshu Ji<sup>2,3,8</sup>, Zhi Ruan<sup>8</sup>,  
6 Xiaoting Hua<sup>1,2,3\*</sup>, Yunsong Yu<sup>1,2,3\*</sup>

7

8 <sup>1</sup>Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University  
9 School of Medicine, Hangzhou, China

10 <sup>2</sup>Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province,  
11 Hangzhou, China

12 <sup>3</sup>Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run  
13 Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

14 <sup>4</sup>Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University  
15 Medical School, Nanjing, China

16 <sup>5</sup>Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College,  
17 Huazhong University of Science and Technology, Wuhan, China

18 <sup>6</sup>Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK

19 <sup>7</sup>Department of Biophysics, Zhejiang University School of Medicine, Hangzhou, China.

20 <sup>8</sup>Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University  
21 School of Medicine, Hangzhou, China.

22 <sup>#</sup>These authors contributed equally to this work.

23

24 \*Correspondence:

25 Xiaoting Hua

26 address: No. 3, East Qingchun Rd, Jianggan District, Hangzhou, China, 310016

27 email: [xiaotinghua@zju.edu.cn](mailto:xiaotinghua@zju.edu.cn)

28 tel: +86-571-86006660

29 Yunsong Yu

30 address: No. 3, East Qingchun Rd, Jianggan District, Hangzhou, China, 310016

31 email: [yvys119@zju.edu.cn](mailto:yvys119@zju.edu.cn)

32 tel: +86-571-86006660

33

## 34 Abstract

35 **Objectives:** This study aimed to characterize *Alcaligenes faecalis* metallo- $\beta$ -lactamases  
36 AFM-2 and AFM-3 from clinical *P. aeruginosa* isolates NDTH10366, NDTH9845 and  
37 WTJH17.

38 **Methods:** Clinical isolates were whole-genome sequenced using the Illumina and Oxford  
39 Nanopore platforms. Minimum inhibitory concentrations (MICs) of clinical isolates and  
40 transformants containing MBL genes were determined using broth microdilution  
41 methods. Kinetic parameters of purified AFM and NDM-1 were measured using a  
42 spectrophotometer. The AFM structure was modelled with SWISS-MODEL.

43 **Results:** NDTH10366 and NDTH9845 were extensively drug-resistant (XDR) isolates  
44 carrying *bla*<sub>AFM-2</sub> and multiple copies of *bla*<sub>KPC-2</sub>, while WTJH17 was an XDR isolate  
45 carrying *bla*<sub>AFM-3</sub>. The plasmid-borne *bla*<sub>AFM-2</sub> and *bla*<sub>AFM-3</sub> genes are associated with a  
46 novel ISCR element, ISCR29. AFM-2 and AFM-3, differing from AFM-1 by one amino  
47 acid substitution each, shared 86.2% and 86.6% amino acid sequence identity with NDM-  
48 1, respectively. Phylogenetic analysis confirmed the close relationship between AFM and  
49 NDM. Expression of AFM and NDM-1 under their native promoters in DH5 $\alpha$  and PAO1  
50 led to elevated MICs for all tested  $\beta$ -lactams except aztreonam. Comparable catalytic  
51 abilities were observed for AFM and NDM-1 when hydrolyzing nitrocefin, cefepime,  
52 imipenem and biapenem, while for other tested  $\beta$ -lactams AFM displayed weaker  
53 enzymatic activities. Modelling AFM structure revealed a characteristic  $\alpha\beta/\beta\alpha$  fold with  
54 two zinc-binding active sites.

55 **Conclusions:** AFM from clinical *P. aeruginosa* isolates demonstrated  $\beta$ -lactamase  
56 activity comparable to NDM-1. Co-carriage of *bla*<sub>AFM</sub> and *bla*<sub>KPC</sub> renders clinical *P.*  
57 *aeruginosa* isolates non-susceptible to all antipseudomonal  $\beta$ -lactams. The association of  
58 *bla*<sub>AFM</sub> genes with translocatable genetic elements and plasmids highlights their  
59 concerning potential for dissemination.

60

61 **Keywords:** *Pseudomonas aeruginosa*, *bla*<sub>AFM-2</sub>, *bla*<sub>AFM-3</sub>, extensively drug-resistant,  
62 metallo- $\beta$ -lactamase

## 63 Introduction

64 Listed as a critical pathogen for which new antibiotics are urgently required [1],  
65 carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) has become a major global  
66 health challenge. Metallo- $\beta$ -lactamases (MBLs) are by far the most common  
67 carbapenemases in CRPA, and can be further divided into subclasses B1a, B1b, B2 and  
68 B3 [2]. Among them, New Delhi metallo- $\beta$ -lactamase (NDM) is of particular concern  
69 because it is often carried by mobile genetic elements that also carry resistance  
70 determinants for other antibiotic classes [3].

71 For much of the past decade, NDM was considered the only member of MBL  
72 subclass B1b. In 2018 another subclass B1b MBL was recognized in an *Alcaligenes*  
73 *faecalis* strain and named *Alcaligenes faecalis* metallo- $\beta$ -lactamase-1 (AFM-1) (GenBank  
74 accession: MK143105). Subsequently, AFM-1 has been found in *Comamonas*  
75 *testosteroni*, *Stenotrophomonas maltophilia* and *Bordetella trematum* (GenBank

76 accessions: MT011984, CP049956, CP049957). However, the biochemical properties of  
77 the AFM enzyme have not been described in detail.

78 Besides MBLs, class A carbapenemases are increasingly being identified in CRPA,  
79 especially *Klebsiella pneumoniae* carbapenemase (KPC). The co-occurrence of KPC and  
80 MBL in *P. aeruginosa* can inactivate all  $\beta$ -lactams including monobactams,  
81 ceftazidime/avibactam and imipenem/relebactam, making clinical treatment extremely  
82 difficult.

83 Here, we report two extensively drug-resistant *P. aeruginosa* (XDR-PA) isolates  
84 carrying *bla*<sub>AFM-2</sub> and multiple copies of *bla*<sub>KPC-2</sub>, and one XDR-PA isolate carrying  
85 *bla*<sub>AFM-3</sub>. We characterized AFM-2 and AFM-3 by comparing their catalytic abilities and  
86 their impacts on antimicrobial susceptibility with AFM-1 and NDM-1.

## 87 Methods

### 88 Bacterial strains and whole genome sequencing

89 All bacterial strains and plasmids used are listed in Table S1. Three clinical *P.*  
90 *aeruginosa* isolates NDTH10366, NDTH9845 and WTJH17 (Table S2) were isolated and  
91 whole-genome sequenced. A hybrid assembly of Nanopore and Illumina sequencing  
92 reads was generated using Unicycler v0.4.8 (<https://github.com/rrwick/Unicycler>).  
93 Prokka v1.14.6 (<https://github.com/tseemann/prokka>) was used for annotation with *P.*  
94 *aeruginosa* PAO1 (GenBank accession: NC\_002516) as the reference. Multi-locus  
95 sequence typing was performed using mlst v2.19.0 (<https://github.com/tseemann/mlst>).  
96 Antibiotic resistance genes were recognized by ABRicate v1.0.1

97 (<https://github.com/tseemann/abricate>) using the NCBI AMRFinderPlus database [4].  
98 Insertion sequences were identified with ISfinder (<https://www-is.biotoul.fr>).

## 99 Antimicrobial susceptibility testing

100 Antimicrobial susceptibility testing was conducted using broth microdilution  
101 methods according to CLSI performance standards [5].

## 102 Plasmid transfer experiments

103 NDTH10366, NDTH9845 and WTJH17 were mated with a rifampin-resistant  
104 derivative of *P. aeruginosa* PAO1 as described previously [6]. Putative transconjugants  
105 were confirmed using PCR with primers listed in Table S3.

## 106 Sequence alignment and phylogenetic tree

107 All amino acid sequences were aligned with ClustalW [7]. The phylogenetic tree  
108 was generated using FastTree v2.1.10 and visualized using iTOL v6.1.1 [8]. Alignment  
109 of AFM-1/2/3 with NDM-1 was visualized using ESPript 3.0 [9].

## 110 Cloning of MBL genes

111 Plasmid pGK1900 was constructed to express MBL genes. Briefly, the region of  
112 plasmid pCasPA [10] containing *oriT*, *traJ* and plasmid pEX18Gm [11] containing GmR  
113 were amplified and recombined into the region of broad-host-range plasmid pACRISPR

114 [10] containing pRO1600 *oriV* and T7 promoter. Eventually, the pGK1900 plasmid was  
115 obtained.

116 The *bla*<sub>NDM-1</sub>, *bla*<sub>AFM-2</sub>, *bla*<sub>AFM-3</sub> genes were amplified from clinical isolates, while  
117 *bla*<sub>AFM-1</sub> was obtained from *bla*<sub>AFM-2</sub> by site-directed mutagenesis using PCR. Both full-  
118 length *bla* genes, and *bla* genes with their upstream promoter regions were amplified and  
119 cloned into pGK1900. The resulting plasmids were transformed into *Escherichia coli*  
120 DH5 $\alpha$  and *P. aeruginosa* PAO1. Minimum inhibitory concentrations (MICs) of  
121 transformants to various antibiotics were then evaluated.

## 122 Expression and purification of MBLs

123 Because the mature AFM-1/2/3 proteins are identical, only the *bla*<sub>NDM-1</sub> and *bla*<sub>AFM-2</sub>  
124 genes, without their signal peptide sequences, were amplified and cloned into pET28a,  
125 introducing an N-terminal His<sub>6</sub>-Tag. The constructed plasmids were transformed into *E.*  
126 *coli* BL21(DE3). Protein expression and purification were carried out as previously  
127 described with some modifications [12]. Briefly, IPTG was added to bacterial culture  
128 reaching an OD<sub>600</sub> of 0.6-0.8, which was then shaken at 18°C overnight. Cells were  
129 harvested and resuspended, then homogenized by a French press. The supernatant was  
130 collected and loaded onto a Ni-column, then the bound protein was eluted. The extract  
131 was loaded onto a Superdex 200 column for further purification. Protein purity (>95%)  
132 was confirmed by SDS-PAGE.



## 133 Measurement of enzyme kinetic parameters

134 Enzymatic activities were measured by a D8 UV-visible spectrophotometer  
135 (Runqee, Shanghai, China) in the assay buffer (10 mM HEPES, 200 mM NaCl, 20  $\mu$ M  
136 ZnCl<sub>2</sub>, pH 7.5) at room temperature. The enzyme kinetic parameters were calculated  
137 using the Michaelis-Menten Equation by GraphPad Prism v9.0.0.

## 138 Modelling of AFM

139 Structure homology-modelling of AFM was achieved using SWISS-MODEL [13].  
140 NDM-1 (Protein Data Bank ID: 4EY2) was adopted as the modelling template. The  
141 resulting model was further analyzed and visualized with PyMOL v2.4.1.

## 142 Ethics statement

143 Approval was obtained from the Ethics Committee of Sir Run Run Shaw Hospital  
144 (approval/reference number: 20201118-49).

## 145 Results

### 146 Complete genome sequences of three XDR-PA isolates

147 Of the antibiotics tested, NDTH10366, NDTH9845 and WTJH17 were only  
148 susceptible to colistin. These isolates were resistant or exhibited reduced susceptibility to  
149 aminoglycosides and fluoroquinolones (Table S4), and were resistant to all tested  $\beta$ -  
150 lactams, even when combined with avibactam (Table 1). Thus, NDTH10366, NDTH9845

151 and WTJH17 were defined as XDR-PA according to the criteria of Magiorakos *et al.*  
152 [14].

153 The complete genomes of NDTH10366, NDTH9845 and WTJH17 consisted of a  
154 circular chromosome and plasmid each (Table S5). NDTH10366 and NDTH9845 belong  
155 to sequence type 463, while WTJH17 belongs to sequence type 260. The replication  
156 initiation genes of pNDTH10366 and pNDTH9845 are identical to that of pBT2101  
157 (GenBank accession CP039991) while pWTJH17's differs by 5 SNPs, indicating that all  
158 three belong to the same globally-disseminated family of megaplasmids that has been  
159 associated with antibiotic resistance genes in *Pseudomonas* since at least the 1970s [15].

160 The acquired antibiotic resistance genes in all three isolates are listed in Table S5.  
161 Notably, NDTH10366 and NDTH9845 contain multiple copies of *bla*<sub>KPC-2</sub>. In both, three  
162 copies of *bla*<sub>KPC-2</sub> were found in the chromosome, in segments flanked by directly-  
163 oriented copies of IS26. The segments are derived from the *bla*<sub>KPC-2</sub> context in *K.*  
164 *pneumoniae* plasmid pKP048 (GenBank accession: FJ628167), relatives of which are the  
165 predominant *bla*<sub>KPC-2</sub>-harboring plasmids in China [16]. A further two copies of *bla*<sub>KPC-2</sub>  
166 are found in pNDTH10366. These are in adjacent 5,270 bp and 5,659 bp segments in a  
167 13,389 bp region that contains three IS26. In addition, pNDTH10366 and pNDTH9845  
168 contain *bla*<sub>OXA-246</sub>, a *bla*<sub>OXA-10</sub>-like non-extended-spectrum  $\beta$ -lactamase [17].

## 169 Genetic context of metallo- $\beta$ -lactamase genes *bla*<sub>AFM-2</sub> and *bla*<sub>AFM-3</sub>

170 Each of the plasmids in the XDR-PA isolates contained an open reading frame  
171 (ORF) that encodes a putative metallo- $\beta$ -lactamase. The ORFs in NDTH10366 and  
172 NDTH9845 were identical, and the ORF in WTJH17 differed at two nucleotide positions.

173 The two different protein sequences were most similar to AFM-1 (GenBank accession:  
174 NG\_063835), differing by just one amino acid each - A15V in the case of NDTH10366  
175 and NDTH9845, and P13S in the case of WTJH17. These two genes were designated  
176 *bla*<sub>AFM-2</sub> and *bla*<sub>AFM-3</sub>, respectively.

177 The *bla*<sub>AFM-2</sub> and *bla*<sub>AFM-3</sub> genes are found in 5,316 bp segments that differ only by  
178 the SNPs that distinguish the genes. The *bla*<sub>AFM</sub>-containing segment is bounded on the  
179 right by a novel *ISCR* element that we have named *ISCR29* and on the left by a 644 bp  
180 fragment from the *ori* end of another *ISCR* element (Figure 1A). The 644 bp remnant is  
181 97.8% identical to the corresponding part of *ISCR29*. The *ISCR*-flanked 3,005 bp  
182 sequence that includes *bla*<sub>AFM-2</sub> resembles the *bla*<sub>NDM-1</sub>-containing passenger segment of  
183 *Tn125* (GenBank accession JN872329) [18] and contains a putative *ble*<sub>MBL</sub> bleomycin  
184 resistance gene (Figure 1A). The region also includes a  $\Delta$ *trpF* gene downstream of  
185 *ble*<sub>MBL</sub> that is truncated by the  $\Delta$ *ISCR* and a 312 bp  $\Delta$ *groEL* upstream of *bla*<sub>AFM-2</sub> that is  
186 83.7% identical to the 3' end of *groEL* of *Tn125*.

187 The *bla*<sub>AFM</sub>-*ISCR29* unit of pNDTH10366 was compared to sequences containing  
188 *bla*<sub>AFM-1</sub> (Figure 1A). This revealed that *bla*<sub>AFM-1</sub> is also associated with *ISCR29*. In the  
189 *bla*<sub>AFM-1</sub>-containing sequences, the 3,005 bp segment that includes *bla*<sub>AFM</sub> and *ble*<sub>MBL</sub>  
190 differed from the sequence in pNDTH10366 by just the SNP that distinguishes *bla*<sub>AFM-1</sub>  
191 from *bla*<sub>AFM-2</sub>. In the *A. faecalis* plasmid pAN70-1, this region has been interrupted by a  
192 10,768 bp insertion comprised of a putative mercury resistance transposon that contains  
193 copies of *IS26* and *IS6100*. The major difference between *bla*<sub>AFM-1</sub> and *bla*<sub>AFM-2</sub>-bearing  
194 sequences was the presence of a  $\Delta$ *ISCR* in *bla*<sub>AFM-1</sub>-associated sequences that is just  
195 96.3% identical to the  $\Delta$ *ISCR* associated with *bla*<sub>AFM-2</sub> in pNDTH10366.

196 The *ISCR29-bla<sub>AFM</sub>* unit is associated with class 1 integrons in

197 XDR-PA

198 The *ISCR29-bla<sub>AFM</sub>* unit in pNDTH10366 lies between two truncated class 1  
199 integrons (Figure 1B). The integron to the left contains the cassette array *aacA7-aadB-*  
200 *cmlA1-aadA24* and a 3'-conserved segment (3'-CS; yellow in Figure 1B) that ends in an  
201 In4-like configuration that includes a copy of the inverted repeat IR<sub>t</sub> and *IS6100* (Figure  
202 1B). The integron to the right is in the same context as In28 [19] adjacent to a complete  
203 *Tn1403* transposition module, but contains the cassette array *aac(6')-IIa-cmlA8-bla<sub>OXA-</sub>*  
204 *246-arr-3-dfrA27* (Figure 1B). The *intI1* gene of the In4-like integron and the 3'-CS of the  
205 *Tn1403*-derived integron have been truncated by the *ISCR29-bla<sub>AFM</sub>* unit.

206 The integrons flanking the *ISCR29-bla<sub>AFM</sub>* unit in pNDTH9845 and pWTJH17 have  
207 been modified by recombination and the actions of translocatable elements. In both, the  
208 region downstream of *sulI* in the In4-like class 1 integron has been replaced (Figure 1C).  
209 The new segment in pNDTH9845 is identical to part of the *Acinetobacter baumannii*  
210 chromosomal resistance island AbGRI3 [20] and contains the aminoglycoside resistance  
211 gene *armA* and macrolide resistance genes *msr(E)-mph(E)*. The *aadA24* gene in this  
212 integron has been interrupted by insertion of *IS1394* in pNDTH9845, and the *aadB* gene  
213 cassette has been lost in pWTJH17 (Figure 1C).

214 The *Tn1403*-derived integrons in pNDTH10366 and pNDTH9845 are identical, but  
215 the one in pWTJH17 has been truncated by an *IS26* that is part of a pseudo-compound  
216 transposon containing *msr(E)-mph(E)* (Figure 1C). The *bla<sub>OXA-246</sub>* gene in the pWTJH17  
217 cassette array has been interrupted by insertion of *ISPre2*.

## 218 Transfer of *bla*<sub>AFM</sub>-bearing plasmids

219 As pBT2101-like plasmids have been reported to be conjugative [15], the  
220 transferability of pNDTH10366, pNDTH9845 and pWTJH17 was tested.  
221 Transconjugants were only obtained from WTJH17-PAO1 mating experiments,  
222 suggesting that only pWTJH17 is conjugative (Figure S1).

## 223 Effects of AFM and NDM on antibiotic susceptibility

224 Alignment revealed that AFM-2 and AFM-3 share 86.2% and 86.6% amino acid  
225 sequence identity with NDM-1, respectively. Major differences were found in the signal  
226 peptide region (Figure 2). Phylogenetic analysis of AFM and other MBLs revealed that  
227 AFM-2 and AFM-3 are subclass B1b MBLs most closely related to the NDM subfamily  
228 (Figure 3).

229 To compare the drug resistance conferred by MBL genes *bla*<sub>AFM-1/2/3</sub> and *bla*<sub>NDM-1</sub>,  
230 they were cloned into pGK1900 and transformed into *E. coli* DH5 $\alpha$  and *P. aeruginosa*  
231 PAO1. The MICs of various antibiotics against transformants were assessed (Table 1).  
232 When expressing MBLs from the T7 promoter, all transformants showed no or low-level  
233 resistance to  $\beta$ -lactams and  $\beta$ -lactam + inhibitor combination agents. A significant  
234 increase in MICs was observed when MBLs were expressed from native promoters.  
235 Interestingly, in *E. coli* DH5 $\alpha$ , resistance levels conferred by *bla*<sub>AFM-1/2/3</sub> under their  
236 native promoters were much lower than that of *bla*<sub>NDM-1</sub>. In contrast, *P. aeruginosa* PAO1  
237 transformants carrying *bla*<sub>AFM-1/2/3</sub> with their native promoters exhibited much higher  
238 MICs than *bla*<sub>NDM-1</sub> to all tested  $\beta$ -lactams except aztreonam.

## 239 Comparison of AFM and NDM kinetic parameters

240 Hydrolyzing abilities of AFM and NDM-1 were tested for aztreonam and other  $\beta$ -  
241 lactams (Table 2). As predicted, both AFM and NDM-1 had no catalytic effect on  
242 aztreonam. For all tested  $\beta$ -lactams except nitrocefin and ertapenem, AFM exhibited  
243 higher affinities but lower turnover numbers than NDM-1, which was indicated by  $K_M$   
244 and  $k_{cat}$  values. Similar catalytic efficiencies between AFM and NDM-1 were observed  
245 for nitrocefin, cefepime, imipenem and biapenem, as indicated by  $k_{cat}/K_M$  values.  
246 However, compared with NDM-1, AFM displayed lower catalytic efficiencies for  
247 penicillin G, ampicillin, carbenicillin, cefuroxime, cefotaxime, ceftazidime, meropenem,  
248 ertapenem.

## 249 Structural modelling of AFM

250 The structure of AFM was modelled using NDM-1 as the reference homology  
251 template. The overall fold of AFM was predicted to be the classic  $\alpha\beta/\beta\alpha$  sandwich, which  
252 is common to all MBLs (Figure 4). Two zinc ions bound in the active sites of AFM, with  
253 Zn1 interacted with histidine residues 117, 119 and 186 at coordination distances of  
254 2.07 Å, 1.88 Å, 2.04 Å, Zn2 interacted with residues Asp121, Cys205 and His247 at  
255 coordination distances of 2.05 Å, 2.42 Å, 1.92 Å (Figure 4).

## 256 Discussion

257 Clinical *P. aeruginosa* isolates NDTH10366, NDTH9845 and WTJH17 are XDR  
258 and sensitive only to colistin. Our analysis of  $bla_{AFM-2/3}$  from clinical isolates and  $bla_{AFM-}$

259  $\beta$ -bearing sequences in GenBank allowed us to characterize the contexts of AFM  
260 determinants and assess their potential for horizontal dissemination. These genes are  
261 associated with a novel ISCR element, ISCR29, which is likely responsible for their  
262 mobility. ISCR elements have been responsible for the dissemination of multiple  
263 resistance determinants, including NDM gene variants [21]. Concerningly, the *bla*<sub>AFM</sub>  
264 genes in pNDTH10366, pNDTH9845 and pWTJH17 are already found in close proximity  
265 to multiple copies of IS26, which is arguably the most important translocatable element  
266 associated with antibiotic resistance genes [22]. It appears that there is significant  
267 potential for IS26 to capture *bla*<sub>AFM-2</sub> from its current context and contribute to its wider  
268 dissemination. This appears to have occurred in the case of *bla*<sub>NDM-1</sub> [23] which, like the  
269 *bla*<sub>AFM</sub> genes, is thought to have originally been mobilized by an ISCR element [24].

270 pNDTH10366, pNDTH9845 and pWTJH17 are all members of the pBT2101-like  
271 megaplasmid family [15]. Plasmids in this family can carry diverse antimicrobial  
272 resistance genes and are widely distributed, both geographically and amongst  
273 *Pseudomonas* hosts in which they are stable and do not impose a measurable fitness cost  
274 [15]. The association of *bla*<sub>AFM</sub> genes with pBT2101-like plasmids in *P. aeruginosa* may  
275 potentiate their rapid spread within the genus, which warrants continuous surveillance.

276 To the best of our knowledge, this is the first report of an MBL-producing *P.*  
277 *aeruginosa* co-harboring five copies of the *bla*<sub>KPC-2</sub> gene. Co-expression of *bla*<sub>KPC-2</sub> and  
278 *bla*<sub>AFM-2</sub> in NDTH10366 and NDTH9845 conferred high-level and broad-range resistance  
279 to all antipseudomonal  $\beta$ -lactams, including aztreonam/avibactam. This could be  
280 explained by two factors. First, high-level expression of KPC-2 could not be totally  
281 inhibited by avibactam due to its high copy number, as previously reported [25]. Second,

282 mechanisms other than  $\beta$ -lactamases may be involved in aztreonam resistance, such as  
283 the upregulation of efflux pump systems [26].

284 From our evaluation, the ability of AFM to hydrolyze some antibiotics was slightly  
285 weaker than NDM-1. This could be explained by certain amino acid differences within  
286 AFM and NDM-1. For example, residues Leu65 and Met67 in NDM-1 are changed to  
287 Met and Val in AFM, respectively. Residues Leu65 and Met67 of NDM-1 have been  
288 reported to form strong hydrophobic interactions with the phenyl ring of penicillin or  
289 ampicillin [27]. These substitutions could lead to the alteration of loop conformation and  
290 hydrophobicity, thus indirectly influencing the enzymatic activities of AFM.

291 In conclusion, we have described the genetic contexts of *bla*<sub>AFM</sub> MBL genes, and  
292 demonstrated that their products exhibit  $\beta$ -lactamase activity comparable to that of NDM-  
293 1. The association of *bla*<sub>AFM</sub> genes with translocatable genetic elements and plasmids  
294 highlights their potential for dissemination. That *bla*<sub>AFM-2</sub> and *bla*<sub>AFM-3</sub> have been found in  
295 organisms as clinically relevant as XDR-PA is of great concern. Genomic surveillance  
296 will be required to track the spread of AFM determinants in bacterial populations  
297 globally.

298



299 **Conflicts of interests**

300 The authors declare that they have no conflict of interest.

301

302 **Funding**

303 This study is supported by the National Natural Science Foundation of China (grant  
304 no. 81830069). R.M was supported by the Medical Research Council-National Natural  
305 Science Foundation of China DETECTIVE project (MR/S013660/1).

306

307 **Acknowledgements**

308 We are very grateful to Dr. Quanjiang Ji (ShanghaiTech University, Shanghai,  
309 China) for providing plasmids pCasPA and pACRISPR.

310

311 **Access to data**

312 The nucleotide sequences reported in this study have been submitted to the  
313 EMBL/GenBank databases under accession numbers CP064401 (NDTH10366  
314 chromosome), CP064402 (NDTH10366 plasmid), CP073080 (NDTH9845 chromosome),  
315 CP073081 (NDTH9845 plasmid), CP073082 (WTJH17 chromosome) and CP073083  
316 (WTJH17 plasmid), respectively.

317

318 **Author's contributions**

319 X.H and Y.Y conceived, designed, and coordinated this study. W.Z, Z.C, and H.S  
320 collected the isolates from respective hospitals. Y.L and Y.Z constructed the plasmids  
321 and performed the antimicrobial susceptibility tests. Y.Z, R.M, J.J, and X.H analyzed the

322 genome sequencing data. Y.L, H.K, and Y.F purified the proteins, measured their kinetic  
323 parameters, and analyzed the modelled protein structure. Y.L and Y.Z wrote the initial  
324 version of the manuscript. R.M, W.S, Z.R, X.H, and Y.Y revised the manuscript.  
325

326 **Table 1.** MICs for *Pseudomonas aeruginosa* clinical isolates carrying *bla*<sub>AFM</sub> and transformants containing different MBLs

Strains	Plasmid <sup>a</sup>	MICs (mg/L) determined by broth microdilution methods										
		AMP	PIP	FEP	CAZ	PTZ	CZA	ETP	IPM	MEM	AZT	AZA
NDTH10366	pNDTH10366	/	>1024	>1024	>1024	>256/4	>1024/4	/	1024	>1024	>1024	256/4
NDTH9845	pNDTH9845	/	1024	>1024	>1024	>256/4	>1024/4	/	1024	>1024	1024	32/4
WTJH17	pWTJH17	/	512	>1024	>1024	>256/4	>1024/4	/	1024	>1024	64	32/4
DH5 $\alpha$	pGK1900	2	1	0.03	0.03	1/4	0.06/4	0.008	0.12	0.016	0.06	/
DH5 $\alpha$	pGK1900_NDM-1	4	2	0.03	0.12	2/4	0.12/4	0.008	0.06	0.03	0.25	/
DH5 $\alpha$	pGK1900_NDM-1 P+	>1024	512	128	>1024	256/4	>1024/4	32	16	32	0.06	/
DH5 $\alpha$	pGK1900_AFM-1	4	2	0.03	4	2/4	2/4	0.008	0.12	0.03	0.12	/
DH5 $\alpha$	pGK1900_AFM-1 P+	256	16	2	256	16/4	256/4	0.25	2	0.5	0.06	/
DH5 $\alpha$	pGK1900_AFM-2	2	1	0.12	2	2/4	1/4	0.008	0.06	0.03	0.06	/
DH5 $\alpha$	pGK1900_AFM-2 P+	512	32	8	512	32/4	512/4	0.25	2	1	0.06	/
DH5 $\alpha$	pGK1900_AFM-3	8	2	0.06	4	1/4	2/4	0.008	0.25	0.03	0.12	/
DH5 $\alpha$	pGK1900_AFM-3 P+	512	32	4	256	32/4	512/4	0.5	2	0.5	0.06	/
PAO1	pGK1900	/	4	2	2	8/4	2/4	/	1	1	4	/
PAO1	pGK1900_NDM-1	/	4	4	8	8/4	8/4	/	1	1	4	/
PAO1	pGK1900_NDM-1 P+	/	64	512	>1024	128/4	>1024/4	/	256	128	4	/
PAO1	pGK1900_AFM-1	/	32	16	64	8/4	64/4	/	1	2	4	/
PAO1	pGK1900_AFM-1 P+	/	1024	>1024	>1024	>256/4	>1024/4	/	1024	256	4	/
PAO1	pGK1900_AFM-2	/	8	8	64	16/4	64/4	/	1	2	4	/

PAO1	pGK1900_AFM-2 P+	/	1024	>1024	>1024	>256/4	>1024/4	/	1024	256	4	/
PAO1	pGK1900_AFM-3	/	4	16	128	4/4	128/4	/	2	2	4	/
PAO1	pGK1900_AFM-3 P+	/	1024	>1024	>1024	>256/4	>1024/4	/	1024	256	4	/

327 AMP, ampicillin; PIP, piperacillin; FEP, cefepime; CAZ, ceftazidime; PTZ, piperacillin/tazobactam; CZA, ceftazidime/avibactam; ETP,

328 ertapenem; IPM, imipenem; MEM, meropenem; AZT, aztreonam; AZA, aztreonam/avibactam.

329 <sup>a</sup> P+ indicates MBLs were expressed from their native promoters.

330 **Table 2.** Kinetic parameters of AFM and NDM-1

	AFM			NDM-1		
	$K_M$ ( $\mu\text{M}$ )	$k_{\text{cat}}$ ( $\text{s}^{-1}$ )	$k_{\text{cat}}/K_M$ ( $\text{s}^{-1}\mu\text{M}^{-1}$ )	$K_M$ ( $\mu\text{M}$ )	$k_{\text{cat}}$ ( $\text{s}^{-1}$ )	$k_{\text{cat}}/K_M$ ( $\text{s}^{-1}\mu\text{M}^{-1}$ )
PG	19.25±1.06	18.05±0.08	0.94	54.72±9.30	63.05±4.63	1.17
AMP	21.55±2.58	23.43±0.82	1.10	114.90±6.01	228.18±2.36	1.99
CB	75.81±4.63	19.88±0.54	0.26	149.73±14.14	54.91±3.52	0.37
NCF	3.67±0.57	7.05±0.36	1.95	2.22±0.44	3.97±0.44	1.82
CXM	2.11±0.11	9.40±0.19	4.46	6.54±0.34	46.72±0.91	7.16
CTX	5.45±0.04	9.54±0.07	1.75	14.76±0.14	62.69±0.99	4.25
CAZ	44.74±1.14	20.42±0.14	0.46	79.90±3.05	88.69±2.09	1.11
FEP	28.53±0.49	5.54±0.02	0.19	135.67±5.60	26.58±0.82	0.20
IPM	51.11±3.55	30.47±1.84	0.60	117.86±24.04	70.35±12.28	0.60
MEM	8.88±0.55	3.42±0.11	0.39	27.64±1.09	23.89±0.65	0.86
ETP	13.20±1.50	2.13±0.08	0.16	10.06±0.72	8.67±0.36	0.86
BPM	42.34±1.60	7.60±0.20	0.18	499.70±44.19	59.40±5.30	0.12
AZT	ND	ND	ND	ND	ND	ND

331  $K_M$  and  $k_{\text{cat}}$  values are shown as means  $\pm$  standard deviation from three independent experiments.

332 ND, not detectable.

333 PG, penicillin G; AMP, ampicillin; CB, carbenicillin; NCF, nitrocefin; CXM, cefuroxime; CTX,

334 cefotaxime; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; ETP,

335 ertapenem; BPM, biapenem; AZT, aztreonam.

336

337

338

339

## 340 References

- 341 [1] E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D.L. Monnet, et al.,  
342 Discovery, research, and development of new antibiotics: the WHO priority list of  
343 antibiotic-resistant bacteria and tuberculosis, *The Lancet. Infectious diseases* 18(3)  
344 (2018) 318-27.
- 345 [2] K. Bush, The ABCD's of  $\beta$ -lactamase nomenclature, *Journal of infection and*  
346 *chemotherapy : official journal of the Japan Society of Chemotherapy* 19(4) (2013) 549-  
347 59.
- 348 [3] D.M.P. De Oliveira, B.M. Forde, T.J. Kidd, P.N.A. Harris, M.A. Schembri, S.A.  
349 Beatson, et al., Antimicrobial Resistance in ESKAPE Pathogens, *Clinical microbiology*  
350 *reviews* 33(3) (2020).
- 351 [4] M. Feldgarden, V. Brover, D.H. Haft, A.B. Prasad, D.J. Slotta, I. Tolstoy, et al.,  
352 Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial  
353 Resistance Genotype-Phenotype Correlations in a Collection of Isolates, *Antimicrobial*  
354 *agents and chemotherapy* 63(11) (2019).
- 355 [5] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI  
356 supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
- 357 [6] H. Cai, Y. Zhu, D. Hu, Y. Li, S. Leptihn, B. Loh, et al., Co-harboring of Novel bla  
358 (KPC-2) Plasmid and Integrative and Conjugative Element Carrying Tn6203 in  
359 Multidrug-Resistant *Pseudomonas aeruginosa*, *Frontiers in microbiology* 12 (2021)  
360 674974.

361 [7] M.A. Larkin, G. Blackshields, N.P. Brown, R. Chenna, P.A. McGettigan, H.  
362 McWilliam, et al., Clustal W and Clustal X version 2.0, *Bioinformatics* (Oxford,  
363 England) 23(21) (2007) 2947-8.

364 [8] I. Letunic, P. Bork, Interactive Tree Of Life (iTOL) v4: recent updates and new  
365 developments, *Nucleic acids research* 47(W1) (2019) W256-W59.

366 [9] X. Robert, P. Gouet, Deciphering key features in protein structures with the new  
367 ENDscript server, *Nucleic acids research* 42(Web Server issue) (2014) W320-4.

368 [10] W. Chen, Y. Zhang, Y. Zhang, Y. Pi, T. Gu, L. Song, et al., CRISPR/Cas9-based  
369 Genome Editing in *Pseudomonas aeruginosa* and Cytidine Deaminase-Mediated Base  
370 Editing in *Pseudomonas* Species, *iScience* 6 (2018) 222-31.

371 [11] T.T. Hoang, R.R. Karkhoff-Schweizer, A.J. Kutchma, H.P. Schweizer, A broad-  
372 host-range Flp-FRT recombination system for site-specific excision of chromosomally-  
373 located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa*  
374 mutants, *Gene* 212(1) (1998) 77-86.

375 [12] Z. Liang, L. Li, Y. Wang, L. Chen, X. Kong, Y. Hong, et al., Molecular basis of  
376 NDM-1, a new antibiotic resistance determinant, *PloS one* 6(8) (2011) e23606.

377 [13] A. Waterhouse, M. Bertoni, S. Bienert, G. Studer, G. Tauriello, R. Gumienny, et al.,  
378 SWISS-MODEL: homology modelling of protein structures and complexes, *Nucleic*  
379 *acids research* 46(W1) (2018) W296-W303.

380 [14] A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, C.G. Giske,  
381 et al., Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an  
382 international expert proposal for interim standard definitions for acquired resistance,

383 Clinical microbiology and infection : the official publication of the European Society of  
384 Clinical Microbiology and Infectious Diseases 18(3) (2012) 268-81.

385 [15] A. Cazares, M.P. Moore, J.P.J. Hall, L.L. Wright, M. Grimes, J.G. Emond-Rhéault,  
386 et al., A megaplasmid family driving dissemination of multidrug resistance in  
387 *Pseudomonas*, *Nat Commun* 11(1) (2020) 1370.

388 [16] K.D. Chavda, L. Chen, M.R. Jacobs, R.A. Bonomo, B.N. Kreiswirth, *Molecular*  
389 *Diversity and Plasmid Analysis of KPC-Producing Escherichia coli*, *Antimicrobial agents*  
390 *and chemotherapy* 60(7) (2016) 4073-81.

391 [17] Y. Qing, K.Y. Cao, Z.L. Fang, Y.M. Huang, X.F. Zhang, G.B. Tian, et al., *Outbreak*  
392 *of PER-1 and diversity of  $\beta$ -lactamases among ceftazidime-resistant Pseudomonas*  
393 *aeruginosa clinical isolates*, *Journal of medical microbiology* 63(Pt 3) (2014) 386-92.

394 [18] S. Bontron, P. Nordmann, L. Poirel, *Transposition of Tn125 Encoding the NDM-1*  
395 *Carbapenemase in Acinetobacter baumannii*, *Antimicrobial agents and chemotherapy*  
396 60(12) (2016) 7245-51.

397 [19] H.W. Stokes, L.D. Elbourne, R.M. Hall, *Tn1403, a multiple-antibiotic resistance*  
398 *transposon made up of three distinct transposons*, *Antimicrobial agents and*  
399 *chemotherapy* 51(5) (2007) 1827-9.

400 [20] G.A. Blackwell, K.E. Holt, S.D. Bentley, L.Y. Hsu, R.M. Hall, *Variants of AbGRI3*  
401 *carrying the armA gene in extensively antibiotic-resistant Acinetobacter baumannii from*  
402 *Singapore*, *The Journal of antimicrobial chemotherapy* 72(4) (2017) 1031-39.

403 [21] A.M. Wailan, H.E. Sidjabat, W.K. Yam, N.F. Alikhan, N.K. Petty, A.L. Sartor, et  
404 al., *Mechanisms Involved in Acquisition of blaNDM Genes by IncA/C2 and IncFIY*  
405 *Plasmids*, *Antimicrobial agents and chemotherapy* 60(7) (2016) 4082-8.



406 [22] C.J. Harmer, C.H. Pong, R.M. Hall, Structures bounded by directly-oriented  
407 members of the IS26 family are pseudo-compound transposons, *Plasmid* 111 (2020)  
408 102530.

409 [23] R.E. Weber, M. Pietsch, A. Frühauf, Y. Pfeifer, M. Martin, D. Luft, et al., IS26-  
410 Mediated Transfer of bla (NDM-1) as the Main Route of Resistance Transmission During  
411 a Polyclonal, Multispecies Outbreak in a German Hospital, *Frontiers in microbiology* 10  
412 (2019) 2817.

413 [24] S.R. Partridge, J.R. Iredell, Genetic contexts of bla<sub>NDM-1</sub>, *Antimicrobial agents and*  
414 *chemotherapy* 56(11) (2012) 6065-7; author reply 71.

415 [25] P. Gaibani, M.C. Re, C. Campoli, P.L. Viale, S. Ambretti, Bloodstream infection  
416 caused by KPC-producing *Klebsiella pneumoniae* resistant to ceftazidime/avibactam:  
417 epidemiology and genomic characterization, *Clinical microbiology and infection : the*  
418 *official publication of the European Society of Clinical Microbiology and Infectious*  
419 *Diseases* 26(4) (2020) 516 e1-16 e4.

420 [26] N. Masuda, E. Sakagawa, S. Ohya, N. Gotoh, H. Tsujimoto, T. Nishino, Substrate  
421 specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in  
422 *Pseudomonas aeruginosa*, *Antimicrobial agents and chemotherapy* 44(12) (2000) 3322-7.

423 [27] H. Zhang, Q. Hao, Crystal structure of NDM-1 reveals a common  $\beta$ -lactam  
424 hydrolysis mechanism, *FASEB journal : official publication of the Federation of*  
425 *American Societies for Experimental Biology* 25(8) (2011) 2574-82.

426


427

428 **Table 1.** MICs for *Pseudomonas aeruginosa* clinical isolates carrying *bla*<sub>AFM</sub> and  
429 transformants containing different MBLs

430

431 **Table 2.** Kinetic parameters of AFM and NDM-1


432



433

434 **Figure 1. Contexts of  $bla_{AFM}$  metallo- $\beta$ -lactamase genes.** A) Comparison of  $bla_{AFM}$ -  
 435 ISCR29 units associated with  $bla_{AFM-1}$  and  $bla_{AFM-2}$ . Sequences are shown as coloured  
 436 boxes, with ISCR elements labelled and grey shading linking sequences that are  
 437 essentially identical. Black circles in ISCR elements represent the location of  $oriIS$ . The  
 438 location of a putative promoter for  $bla_{AFM}$  is indicated by an arrow labelled 'P'. Asterisks  
 439 show the locations of single nucleotide polymorphisms and the position of a transposon is

440 marked by a labelled arrow. The source of each structure is indicated to the left. Drawn to  
441 scale from GenBank accessions CP064402, CP049957, CP049956 and MK757441. B)  
442 Context of the *bla*<sub>AFM-2</sub> gene in pNDTH10366. DNA sequence is shown as coloured  
443 boxes with labelled arrows below indicating the location and orientation of genes. IS and  
444 ISCR elements are labelled above. Sequences derived from In4-like and Tn1403-derived  
445 integrons are marked by labelled horizontal lines below. Small rectangles within integron  
446 regions show the positions of *attI* (open rectangles) and *attC* (filled rectangles) sites,  
447 respectively. Inverted repeats are shown as labelled vertical lines. Drawn to scale from  
448 GenBank accession CP064402. C) Comparison of ISCR29-*bla*<sub>AFM</sub> unit contexts in  
449 pNDTH10366 (i), pNDTH9845 (ii) and pWTJH17 (iii). Genetic elements are drawn and  
450 coloured as in panel (B). Grey shading links identical sequences. The identities of IS  
451 shown as coloured boxes are labelled above, and the insertion positions of IS removed to  
452 generate this comparison are shown as labelled vertical arrows. Additional, interrupted or  
453 lost antibiotic resistance genes are labelled. Drawn to scale from GenBank accessions  
454 CP064402, CP073081 and CP073083.  
455  
456



457

458 **Figure 2. Amino acid sequence alignment of AFM-1, AFM-2, AFM-3 with NDM-1.**


459 Sequence alignment was generated by ClustalW and ESPrpt 3.0. The secondary structure

460 of NDM-1 was depicted above the sequence. Residues with alternate conformations are

461 indicated by grey stars. The red arrow represents the head amino acid positions of the

462 mature proteins.

463




464

465

466 **Figure 3. Phylogenetic relationships between AFM and other MBLs.** The tree was  
 467 generated by FastTree v2.1.10 and visualized by iTOL v6.1.1 using midpoint rooting  
 468 method. Labels of the phylogenetic tree are highlighted in different colours based on  
 469 MBL subclasses. AFM-1, AFM-2 and AFM-3 are marked in red. Amino acid sequences  
 470 were obtained from NCBI Bacterial Antimicrobial Resistance Reference Gene Database.

471



472

473

474 **Figure 4. The overall modelling structure of AFM and its active sites bounded with**

475 **zinc ions.** AFM was made up of four layers,  $\alpha/\beta/\beta/\alpha$ . Two zinc ions interacted with

476 residues His117, His119, His186 and residues Asp121, Cys205, His247 in the active

477 sites, respectively. The metal-binding residues within the active sites are displayed as

478 sticks. The zinc ions are coloured in grey. Interactions are shown as dashes.

479

480 **Supporting Information**

481

482 ***Alcaligenes faecalis* metallo- $\beta$ -lactamase in extensively drug-resistant *Pseudomonas***  
483 ***aeruginosa* isolates**

484 **Running Title:** *Alcaligenes faecalis* metallo- $\beta$ -lactamases

485 Yue Li<sup>1,2,3#</sup>, Yiwei Zhu<sup>1,2,3#</sup>, Wanqing Zhou<sup>4#</sup>, Zhongju Chen<sup>5#</sup>, Robert A. Moran<sup>6</sup>,

486 Huanhuan Ke<sup>7</sup>, Yu Feng<sup>7</sup>, Willem van Schaik<sup>6</sup>, Han Shen<sup>4</sup>, Jingshu Ji<sup>2,3,8</sup>, Zhi Ruan<sup>8</sup>,

487 Xiaoting Hua<sup>1,2,3\*</sup>, Yunsong Yu<sup>1,2,3\*</sup>

488

489 <sup>1</sup>Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University  
490 School of Medicine, Hangzhou, China

491 <sup>2</sup>Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province,  
492 Hangzhou, China

493 <sup>3</sup>Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run  
494 Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

495 <sup>4</sup>Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University  
496 Medical School, Nanjing, China

497 <sup>5</sup>Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College,  
498 Huazhong University of Science and Technology, Wuhan, China

499 <sup>6</sup>Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK

500 <sup>7</sup>Department of Biophysics, Zhejiang University School of Medicine, Hangzhou, China.

501 <sup>8</sup>Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University  
502 School of Medicine, Hangzhou, China.

503 <sup>#</sup>These authors contributed equally to this work.



504

505 \*Correspondence:

506 Xiaoting Hua

507 address: No. 3, East Qingchun Rd, Jianggan District, Hangzhou, China, 310016

508 email: [xiaotinghua@zju.edu.cn](mailto:xiaotinghua@zju.edu.cn)

509 tel: +86-571-86006660

510 Yunsong Yu

511 address: No. 3, East Qingchun Rd, Jianggan District, Hangzhou, China, 310016

512 email: [yvys119@zju.edu.cn](mailto:yvys119@zju.edu.cn)

513 tel: +86-571-86006660

514

515 **Table S1. Bacterial strains and plasmids used in this study**

Name	Description	Source/Reference
<u>Strains</u>		
<i>Escherichia coli</i>		
DH5 $\alpha$	Strain for general cloning and plasmid maintenance	TaKaRa
BL21(DE3)	Strain for protein expression	Biomed
ATCC 25922	Quality control strain for antimicrobial susceptibility testing	Lab stock
<i>Klebsiella pneumoniae</i>		
ATCC 700603	Quality control strain for antimicrobial susceptibility testing	Lab stock
<i>Pseudomonas aeruginosa</i>		
PAO1	Standard laboratory <i>P. aeruginosa</i> strain	Lab Stock
ATCC 27853	Quality control strain for antimicrobial susceptibility testing	Lab stock
NDTH10366	Clinical <i>P. aeruginosa</i> isolate carrying <i>bla</i> <sub>AFM-2</sub> and five <i>bla</i> <sub>KPC-2</sub> genes	This study
NDTH9845	Clinical <i>P. aeruginosa</i> isolate carrying <i>bla</i> <sub>AFM-2</sub> and three <i>bla</i> <sub>KPC-2</sub> genes	This study
WTJH17	Clinical <i>P. aeruginosa</i> isolate carrying <i>bla</i> <sub>AFM-3</sub>	This study
<u>Plasmids</u>		
pNDTH10366	Plasmid of NDTH10366	This study
pNDTH9845	Plasmid of NDTH9845	This study
pWTJH17	Plasmid of WTJH17	This study
pACRISPR	Guide RNA expression vector containing pRO1600 <i>oriV</i> and T7 promoter	<sup>1</sup>

pCasPA	Cas9 nuclease expression vector containing <i>oriT</i> , <i>traJ</i>	1
pEX18Gm	Suicide vector; Gm <sup>R</sup>	2
pGK1900	Broad-host-range cloning vector with T7 promoter; Gm <sup>R</sup>	This study
pGK1900_AFM-1	pGK1900 carrying <i>bla</i> <sub>AFM-1</sub> inserted downstream of T7 promoter	This study
pGK1900_AFM-1 P+	pGK1900 carrying <i>bla</i> <sub>AFM-1</sub> and its upstream promoter regions inserted downstream of T7 promoter	This study
pGK1900_AFM-2	pGK1900 carrying <i>bla</i> <sub>AFM-2</sub> inserted downstream of T7 promoter	This study
pGK1900_AFM-2 P+	pGK1900 carrying <i>bla</i> <sub>AFM-2</sub> and its upstream promoter regions inserted downstream of T7 promoter	This study
pGK1900_AFM-3	pGK1900 carrying <i>bla</i> <sub>AFM-3</sub> inserted downstream of T7 promoter	This study
pGK1900_AFM-3 P+	pGK1900 carrying <i>bla</i> <sub>AFM-3</sub> and its upstream promoter regions inserted downstream of T7 promoter	This study
pGK1900_NDM-1	pGK1900 carrying <i>bla</i> <sub>NDM-1</sub> inserted downstream of T7 promoter	This study
pGK1900_NDM-1 P+	pGK1900 carrying <i>bla</i> <sub>NDM-1</sub> and its upstream promoter regions inserted downstream of T7 promoter	This study
pET28a	Bacterial vector for protein expression; Km <sup>R</sup>	Novagen
pET28a_NDM-1	pET28a carrying a N-terminally His <sub>6</sub> -tagged NDM-1 without signal peptide	This study
pET28a_AFM-2	pET28a carrying a N-terminally His <sub>6</sub> -tagged AFM-2 without signal peptide	This study

516 References

- 517 1. Chen W, Zhang Y, Zhang Y, et al. CRISPR/Cas9-based Genome Editing in *Pseudomonas aeruginosa* and Cytidine Deaminase-Mediated  
518 Base Editing in *Pseudomonas* Species. *iScience* 2018; **6**: 222-31.

519 2. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP. A broad-host-range Flp-FRT recombination system for site-specific  
520 excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* 1998;  
521 **212**(1): 77-86.

522 **Table S2. Clinical information of *Pseudomonas aeruginosa* strains NDTH10366, NDTH9845 and WTJH17 harboring *bla*<sub>AFM</sub>**

Strains	Area	Hospital	Department	Collection Date	Patient Age (yrs)	Patient Gender	Sample Source	Infection Site	Anti-PA Treatment	Outcome
NDTH10366	Eastern China	NDTH	ICU	Jan-2019	55	Male	Urine	Urinary tract colonization	/	Recovered
NDTH9845	Eastern China	NDTH	NICU	Nov-2018	63	Female	Urine	Urinary tract colonization	/	Recovered
WTJH17	Central China	WTJH	ICU	Feb-2018	44	Male	Blood	Bloodstream infection	Colistin	Dead

523 NDTH, Nanjing Drum Tower Hospital; WTJH, Wuhan Tongji Hospital; ICU, intensive care unit; NICU, neurosurgery intensive care unit.

524 **Table S3. Primers used for putative transconjugants confirmation in this work**

Genes	Primer Sequences (5'→3')
<i>bla</i> <sub>AFM</sub>	<b>F:</b> TGCTAATGGCACCCCTTTGACATC <b>R:</b> GCGTTGCAGGATCATCCAGC
PA1935	<b>F:</b> CCACGTCATAGTCGCTCGATTTCTTCCGCCCTG <b>R:</b> GGATGACTTCGCAGTGATGGCGCAGC
Replication initiation genes of pNDTH10366, pNDTH9845 and pWTJH17	<b>F:</b> ATGGATGTAATCGAATCACAGAACGACTTGC <b>R:</b> CTGCCGGCAGACGACAGGTC

525

526

527 **Table S4. MICs of aminoglycosides, fluoroquinolones and colistin for**  
 528 *Pseudomonas aeruginosa* clinical isolates carrying *bla*<sub>AFM</sub>

Strains	MICs (mg/L)					
	AK	GM	TM	CIP	LEV	COL
NDTH10366	>64	>64	>64	16	>32	0.25
NDTH9845	>64	>64	>64	16	>32	1
WTJH17	32	64	64	>16	32	1

529 AK, amikacin; GM, gentamicin; TM, tobramycin; CIP, ciprofloxacin; LEV,  
 530 levofloxacin; COL, colistin.

531 **Table S5. Genome characteristics of XDR *Pseudomonas aeruginosa***

Isolate	Molecule	Size (bp)	Acquired antibiotic resistance genes
NDTH10366	chromosome	6,974,425	<i>bla</i> <sub>KPC-2</sub> (x3), <i>sul1</i> , <i>aadB</i> , <i>aac(6')-IIa</i> , <i>catB7</i> , <i>crpP</i> (x2)
	pNDTH10366	392,244	<i>bla</i> <sub>KPC-2</sub> (x2), <i>sul1</i> (x2), <i>aadA24</i> , <i>cmlA1</i> , <i>aadB</i> , <i>aacA7</i> , <i>dfrA27</i> , <i>arr-3</i> , <i>bla</i> <sub>OXA-246</sub> , <i>cmlA8</i> , <i>aac(6')-IIa</i> , <i>ble</i> <sub>MBL</sub> , <i>bla</i> <sub>AFM-2</sub>
NDTH9845	chromosome	7,137,026	<i>bla</i> <sub>KPC-2</sub> (x3), <i>sul1</i> , <i>aadB</i> , <i>aac(6')-IIa</i> , <i>catB7</i> , <i>bla</i> <sub>CARB-2</sub> , <i>aph(3')-VI</i> , <i>crpP</i> (x3)
	pNDTH9845	463,517	<i>sul1</i> (x3), <i>cmlA1</i> , <i>aadB</i> , <i>aacA7</i> , <i>dfrA27</i> , <i>arr-3</i> , <i>bla</i> <sub>OXA-246</sub> , <i>cmlA8</i> , <i>aac(6')-IIa</i> , <i>ble</i> <sub>MBL</sub> , <i>bla</i> <sub>AFM-2</sub> , <i>msr(E)-mph(E)</i> , <i>armA</i> , <i>qnrVC1</i> , <i>dfrA22</i>
WTJH17	chromosome	6,389,938	<i>catB7</i> , <i>bla</i> <sub>CARB-4</sub>
	pWTJH17	436,486	<i>sul1</i> (x3), <i>aadA24</i> , <i>cmlA1</i> , <i>aacA7</i> , <i>dfrA27</i> , <i>arr-3</i> , <i>cmlA8</i> , <i>aac(6')-IIa</i> , <i>ble</i> <sub>MBL</sub> , <i>bla</i> <sub>AFM-3</sub> , <i>msr(E)-mph(E)</i> , <i>qnrVC1</i> , <i>aadA1</i> , <i>catB2</i> -like


532 Antibiotic resistance genes were detected with abricate using the ResFinder database. Only complete, uninterrupted genes are listed.

533 Chromosomal *bla*<sub>PAO</sub>, *bla*<sub>OXA-396/486</sub>, *fosA* and *aph(3')-IIB* were considered intrinsic *P. aeruginosa* genes. *aacA7* is also called *aac(6')*-

534 *II*. *aadB* is also called *ant(2'')-Ia*.



535



536

537 **Figure S1. Agarose gel electrophoresis of PCR-amplified products from**  
538 **WTJH17, PAO1 and their transconjugant.** (A) Lane M1 = 5000 bp DNA marker;  
539 lane 1 = WTJH17 (amplified for *bla*<sub>AFM-3</sub>); lane 2 = PAO1 (amplified for *bla*<sub>AFM-3</sub>);  
540 lane 3 = transconjugant (amplified for *bla*<sub>AFM-3</sub>); lane 4 = WTJH17 (amplified for  
541 PAO1-specific PA1935); lane 5 = PAO1 (amplified for PAO1-specific PA1935); lane  
542 6 = transconjugant (amplified for PAO1-specific PA1935). (B) Lane M2 = 5000 bp  
543 DNA marker; lane 7 = WTJH17 (amplified for pWTJH17 replication initiation gene);  
544 lane 8 = transconjugant (amplified for pWTJH17 replication initiation gene); lane 9 =  
545 PAO1 (amplified for pWTJH17 replication initiation gene). Primers used were listed  
546 in Table S3.

547

548

549

550